[Clinical update in critical care of pulmonary medicine 2024]

This review outlines significant clinical research developments in the field of critical care respiratory medicine from October 2023 to September 2024. In the post-pandemic era, the new global definition of acute respiratory distress syndrome (ARDS) has improved practicality and early warning capabilities, although further refinement through respiratory mechanics and multi-omics approaches is required. Novel patterns of pulmonary microbiota distribution in ARDS patients have emerged, with microbiota-host immune interactions significantly influencing clinical outcomes. Limitations of conventional antiviral and broad-spectrum immunosuppressive therapies have prompted exploration of novel approaches in cell survival regulation and immune maintenance, while modulation of fibroblast phenotypic transformation holds promise for effective repair after severe lung injury. The development of risk prediction tools and machine learning models, which integrate multidimensional bioinformatics data, presents novel opportunities for stratified patient management in critical care and the implementation of intelligent ICU systems. Personalized respiratory support has progressed in the areas of optimal oxygenation targets, positive end-expiratory pressure titration, and extracorporeal membrane oxygenation. While breakthrough therapeutic agents remain elusive, innovations in traditional critical care medication management (vasopressors, sedatives, and proton pump inhibitors) have yielded significant benefits, demonstrating that the field continues to evolve towards more personalized approaches.